To product overview AustriaTo global product overview
Supraventricular tachycardia and for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other circumstances where short-term control of the ventricular rate with a short acting agent is desirable. Non-compensatory sinus tachycardia where, in the physician’s judgment the rapid heart rate requirs specific intervention.
Landiolol is not intended for use in chronic settings.
Active ingredient: Landiolol | Pharmaceutical form: Concentrate & powder for the Injection solution | Strength: 20 mg/2 ml (concentrate), 300 mg (powder)
Marketing authorisation holder: Amomed Pharma GmbH